Drug Approval | June 27, 2023
Moderna files for FDA authorization of its Covid-19 Vaccine
Supply readiness follows months of manufacturing to ensure timely and ample supply
Supply readiness follows months of manufacturing to ensure timely and ample supply
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
